StreetAlpha.app
Home › Stocks › XNCR

Xencor Inc (XNCR)

Healthcare
$33.26
▼ −2.21%
LAST CLOSE · NOV 20

Xencor develops engineered antibody drugs for cancer and autoimmune diseases and partners with other drugmakers on its technology. It last closed at $33.26 on Nov 20, down 2.21% on the day. The next earnings report for XNCR is expected around Wed, Feb 24, 2027, after the close. For the quarter ended Sep 2026, XNCR reported EPS of $0.50 on revenue of $116.5M, with revenue up 454.9% from a year ago. Over its last 8 reports the stock moved an average of 8.1% the session after earnings. Over the last 12 months XNCR insiders bought $0 of stock on the open market and sold $7.5M, according to SEC Form 4 filings.

AI Auto Pilots
Is XNCR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold XNCR.

Key Stats

Last 12 months
Results
Revenue
$200.5M
+33.5% vs a year ago
Net income
−$117.9M
−58.8% margin
EPS (diluted)
−$1.56
Free cash flow
−$176.4M
−88.0% margin
Valuation
Market cap
$2.5B
75.0M shares
P/E
–
No P/E while losing money
Price to sales
12.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$59.6M
At Sep 30
Debt
$95.1M
At Sep 30
Shareholder equity
$560.4M
Shares outstanding
75.0M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $275.1M$275.1MFY2021FY2022: $164.6M$164.6MFY2022FY2023: $174.6M$174.6MFY2023FY2024: $110.5M$110.5MFY2024FY2025: $125.6M$125.6MFY2025

From XNCR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Feb 24
Estimated date · After the close
Reported EPS
$0.50
Quarter ended Sep 2026
Year ago EPS
-$0.08
Same quarter last year
Revenue
$116.5M
+454.9% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.58Dec '24Mar 2025: -$0.66Mar '25Jun 2025: -$0.41Jun '25Sep 2025: -$0.08Sep '25Dec 2025: -$0.09Dec '25Mar 2026: -$1.71Mar '26Jun 2026: -$0.29Jun '26Sep 2026: $0.50Sep '26Latest $0.50
Revenue by quarter
Dec 2024: $52.8MDec '24Mar 2025: $32.7MMar '25Jun 2025: $43.6MJun '25Sep 2025: $21.0MSep '25Dec 2025: $28.2MDec '25Mar 2026: $4.5MMar '26Jun 2026: $51.2MJun '26Sep 2026: $116.5MSep '26Latest $116.5M
How XNCR moved after its last 8 reports
Average move the session after a report ±8.1%
Oct 26, 2026Time not announced+15.9%
Jul 29, 2026After the close+10.0%
May 6, 2026After the close−5.4%
Feb 25, 2026After the close+13.1%
Jan 8, 2026Time not announced−5.1%
Nov 5, 2025After the close−2.6%
Aug 6, 2025After the close−2.3%
May 7, 2025After the close+10.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on XNCRStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on XNCR
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on XNCR

Technical Analysis

XNCR · as of the Nov 20 close · updated each morning
Uptrend

The stock sits between its 20 and 50 day averages. It is 44% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 53). The nearest support is the Pivot S1 at $32.83, and the nearest resistance the Pivot at $33.55.

Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityNormal, 5.8%/day
Key levels
$40.6052 week high+22.1%
$33.98Pivot R1+2.2%
$33.9020 day average+1.9%
$33.60Swing high (Oct 26)+1.0%
$33.55Pivot+0.9%
$33.26Last close
$32.83Pivot S1−1.3%
$28.2650 day average−15.0%
$25.80Swing low (Aug 28)−22.4%
$25.03100 day average−24.7%
$18.67200 day average−43.9%
$10.3852 week low−68.8%
Indicators
RSI (14)53.40Middle of its rangeNeutral
MACD2.11Below its signal lineBearish
Stochastic41.4Middle of its rangeNeutral
ADX (14)34.9Trending up
Williams %R-66.8Oversold below −80, overbought above −20Neutral
CCI (20)-8.8Oversold below −100, overbought above 100Neutral
Rate of change−7.0%Change over 10 sessionsBearish
ATR (14)$1.94Typical daily range, 5.8% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for XNCR

What happened before

See how XNCR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow XNCR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How XNCR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for XNCRHow many large options trades hit XNCR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

XNCR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲120 buying vs 96 selling
  • ▲Held by funds +4.8 pts
  • ▲Funds holding +26
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding234208+12.5%
In funds' top 1042+100.0%
Held by funds116.9%112.2%+4.8 pts
New / increased46 / 7430 / 84+5.3%
Reduced / sold out76 / 2056 / 24+20.0%
Put/call ratio1.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See XNCR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

XNCR Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$7.5M17 sales · 9 insiders
5% of the selling was under pre-arranged trading plans.
2025-12 sold $3.0M2026-03 sold $528K2026-04 sold $43K2026-06 sold $379K2026-11 sold $3.6MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 11Bart Jan CornelissenSr. Vice President & CFOSale10,100$39.82$402K
Nov 10Richard J RanieriDirectorSale81,252$39.25$3.2M
Jun 18Ellen FeigalDirectorSale plan6,843$13.06$89K
Jun 15Kevin Charles GormanDirectorSale plan7,527$12.31$93K
Jun 15Richard J RanieriDirectorSale plan5,474$12.31$67K
Jun 15Alan Bruce MontgomeryDirectorSale plan5,064$12.31$62K
Every insider buy and sale for XNCR over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See XNCR insider trades →

From SEC Form 4 filings by XNCR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XNCR is in one of them and how their past XNCR trades turned out.

XNCR in the AI portfolios
Loading…

XNCR News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered XNCR in an article yet. Here's the latest on the wider market.

XNCR in the news

About Xencor

Xencor is a biopharmaceutical company based in Pasadena, California, that designs engineered antibody drugs. Its work focuses on cancer and autoimmune diseases, and it uses its own protein engineering technology to build antibody drug candidates, several of which are in clinical trials. The company also licenses its antibody design technology to pharmaceutical and biotechnology partners, who may develop or market the resulting medicines.

Headquarters
Pasadena, CA